These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12370388)

  • 1. Differences between T cell epitopes recognized after immunization and after infection.
    Vogel TU; Horton H; Fuller DH; Carter DK; Vielhuber K; O'Connor DH; Shipley T; Fuller J; Sutter G; Erfle V; Wilson N; Picker LJ; Watkins DI
    J Immunol; 2002 Oct; 169(8):4511-21. PubMed ID: 12370388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
    Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
    J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
    Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
    J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
    Horton H; Vogel TU; Carter DK; Vielhuber K; Fuller DH; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Montefiori DC; Erfle V; Desrosiers RC; Wilson N; Picker LJ; Wolinsky SM; Wang C; Allison DB; Watkins DI
    J Virol; 2002 Jul; 76(14):7187-202. PubMed ID: 12072518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.
    Kwa S; Lai L; Gangadhara S; Siddiqui M; Pillai VB; Labranche C; Yu T; Moss B; Montefiori DC; Robinson HL; Kozlowski PA; Amara RR
    J Virol; 2014 Sep; 88(17):9579-89. PubMed ID: 24920805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251.
    Nacsa J; Edghill-Smith Y; Tsai WP; Venzon D; Tryniszewska E; Hryniewicz A; Moniuszko M; Kinter A; Smith KA; Franchini G
    J Immunol; 2005 Feb; 174(4):1913-21. PubMed ID: 15699118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection.
    Martins MA; Tully DC; Cruz MA; Power KA; Veloso de Santana MG; Bean DJ; Ogilvie CB; Gadgil R; Lima NS; Magnani DM; Ejima K; Allison DB; Piatak M; Altman JD; Parks CL; Rakasz EG; Capuano S; Galler R; Bonaldo MC; Lifson JD; Allen TM; Watkins DI
    J Virol; 2015 Nov; 89(21):10802-20. PubMed ID: 26292326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the immune response and viral evolution during the acute phase of SIV infection.
    Horton H; Vogel T; O'Connor D; Picker L; Watkins DI
    Vaccine; 2002 May; 20(15):1927-32. PubMed ID: 11983247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
    Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
    J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope.
    Sarkar S; Kalia V; Murphey-Corb M; Montelaro RC
    J Immunol; 2002 Apr; 168(8):4001-11. PubMed ID: 11937557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of SIV-lipopeptide immunizations administered by the intradermal route in their ability to induce antigen specific T-cell responses in rhesus macaques.
    Coutsinos Z; Villefroy P; Gras-Masse H; Guillet JG; Bourgault-Villada I
    FEMS Immunol Med Microbiol; 2005 Mar; 43(3):357-66. PubMed ID: 15708309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
    Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
    J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination.
    Velu V; Kannanganat S; Ibegbu C; Chennareddi L; Villinger F; Freeman GJ; Ahmed R; Amara RR
    J Virol; 2007 Jun; 81(11):5819-28. PubMed ID: 17376899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.
    Nacsa J; Radaelli A; Edghill-Smith Y; Venzon D; Tsai WP; Morghen Cde G; Panicali D; Tartaglia J; Franchini G
    Vaccine; 2004 Jan; 22(5-6):597-606. PubMed ID: 14741150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal and systemic SIV-specific cytotoxic CD4
    Khanna M; Jackson RJ; Alcantara S; Amarasena TH; Li Z; Kelleher AD; Kent SJ; Ranasinghe C
    Sci Rep; 2019 Apr; 9(1):5661. PubMed ID: 30952887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques.
    Carnathan DG; Wetzel KS; Yu J; Lee ST; Johnson BA; Paiardini M; Yan J; Morrow MP; Sardesai NY; Weiner DB; Ertl HC; Silvestri G
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):518-23. PubMed ID: 25550504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses.
    Malkevitch NV; Patterson LJ; Aldrich MK; Wu Y; Venzon D; Florese RH; Kalyanaraman VS; Pal R; Lee EM; Zhao J; Cristillo A; Robert-Guroff M
    Virology; 2006 Sep; 353(1):83-98. PubMed ID: 16814356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrogation of AIDS vaccine-induced cytotoxic T-lymphocyte efficacy in vivo due to a change in viral epitope flanking sequences.
    Moriya C; Igarashi H; Takeda A; Tsukamoto T; Kawada M; Yamamoto H; Inoue M; Iida A; Shu T; Hasegawa M; Nagai Y; Matano T
    Microbes Infect; 2008 Mar; 10(3):285-92. PubMed ID: 18316225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.